Global Gastric Inhibitory Polypeptide Receptor Market Growth 2022-2028

January 2022 | 90 pages | ID: GD2902C9D03CEN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

As the global economy mends, the 2021 growth of Gastric Inhibitory Polypeptide Receptor will have significant change from previous year. According to our (LP Information) latest study, the global Gastric Inhibitory Polypeptide Receptor market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Gastric Inhibitory Polypeptide Receptor market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.

The United States Gastric Inhibitory Polypeptide Receptor market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Gastric Inhibitory Polypeptide Receptor market, reaching US$ million by the year 2028. As for the Europe Gastric Inhibitory Polypeptide Receptor landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.

Global main Gastric Inhibitory Polypeptide Receptor players cover Alchemia Limited, AstraZeneca Plc, Carmot Therapeutics, Inc., and Diabetica Limited, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

This report presents a comprehensive overview, market shares, and growth opportunities of Gastric Inhibitory Polypeptide Receptor market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6

• HM-15211
• LBT-6030
• LY-3298176
• NNC-92041706
• Others

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.

• Metabolic Disorder
• Type 2 Diabetes
• Obesity
• Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include

• Alchemia Limited
• AstraZeneca Plc
• Carmot Therapeutics, Inc.
• Diabetica Limited
• Longevity Biotech, Inc
• Novo Nordisk A/S
• Sanofi
• Zealand Pharma A/S

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Gastric Inhibitory Polypeptide Receptor Annual Sales 2017-2028
  2.1.2 World Current & Future Analysis for Gastric Inhibitory Polypeptide Receptor by Geographic Region, 2017, 2022 & 2028
  2.1.3 World Current & Future Analysis for Gastric Inhibitory Polypeptide Receptor by Country/Region, 2017, 2022 & 2028
2.2 Gastric Inhibitory Polypeptide Receptor Segment by Type
  2.2.1 HM-15211
  2.2.2 LBT-6030
  2.2.3 LY-3298176
  2.2.4 NNC-92041706
  2.2.5 Others
2.3 Gastric Inhibitory Polypeptide Receptor Sales by Type
  2.3.1 Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2017-2022)
  2.3.2 Global Gastric Inhibitory Polypeptide Receptor Revenue and Market Share by Type (2017-2022)
  2.3.3 Global Gastric Inhibitory Polypeptide Receptor Sale Price by Type (2017-2022)
2.4 Gastric Inhibitory Polypeptide Receptor Segment by Application
  2.4.1 Metabolic Disorder
  2.4.2 Type 2 Diabetes
  2.4.3 Obesity
  2.4.4 Others
2.5 Gastric Inhibitory Polypeptide Receptor Sales by Application
  2.5.1 Global Gastric Inhibitory Polypeptide Receptor Sale Market Share by Application (2017-2022)
  2.5.2 Global Gastric Inhibitory Polypeptide Receptor Revenue and Market Share by Application (2017-2022)
  2.5.3 Global Gastric Inhibitory Polypeptide Receptor Sale Price by Application (2017-2022)

3 GLOBAL GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR BY COMPANY

3.1 Global Gastric Inhibitory Polypeptide Receptor Breakdown Data by Company
  3.1.1 Global Gastric Inhibitory Polypeptide Receptor Annual Sales by Company (2020-2022)
  3.1.2 Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Company (2020-2022)
3.2 Global Gastric Inhibitory Polypeptide Receptor Annual Revenue by Company (2020-2022)
  3.2.1 Global Gastric Inhibitory Polypeptide Receptor Revenue by Company (2020-2022)
  3.2.2 Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Company (2020-2022)
3.3 Global Gastric Inhibitory Polypeptide Receptor Sale Price by Company
3.4 Key Manufacturers Gastric Inhibitory Polypeptide Receptor Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Gastric Inhibitory Polypeptide Receptor Product Location Distribution
  3.4.2 Players Gastric Inhibitory Polypeptide Receptor Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR BY GEOGRAPHIC REGION

4.1 World Historic Gastric Inhibitory Polypeptide Receptor Market Size by Geographic Region (2017-2022)
  4.1.1 Global Gastric Inhibitory Polypeptide Receptor Annual Sales by Geographic Region (2017-2022)
  4.1.2 Global Gastric Inhibitory Polypeptide Receptor Annual Revenue by Geographic Region
4.2 World Historic Gastric Inhibitory Polypeptide Receptor Market Size by Country/Region (2017-2022)
  4.2.1 Global Gastric Inhibitory Polypeptide Receptor Annual Sales by Country/Region (2017-2022)
  4.2.2 Global Gastric Inhibitory Polypeptide Receptor Annual Revenue by Country/Region
4.3 Americas Gastric Inhibitory Polypeptide Receptor Sales Growth
4.4 APAC Gastric Inhibitory Polypeptide Receptor Sales Growth
4.5 Europe Gastric Inhibitory Polypeptide Receptor Sales Growth
4.6 Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales Growth

5 AMERICAS

5.1 Americas Gastric Inhibitory Polypeptide Receptor Sales by Country
  5.1.1 Americas Gastric Inhibitory Polypeptide Receptor Sales by Country (2017-2022)
  5.1.2 Americas Gastric Inhibitory Polypeptide Receptor Revenue by Country (2017-2022)
5.2 Americas Gastric Inhibitory Polypeptide Receptor Sales by Type
5.3 Americas Gastric Inhibitory Polypeptide Receptor Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Gastric Inhibitory Polypeptide Receptor Sales by Region
  6.1.1 APAC Gastric Inhibitory Polypeptide Receptor Sales by Region (2017-2022)
  6.1.2 APAC Gastric Inhibitory Polypeptide Receptor Revenue by Region (2017-2022)
6.2 APAC Gastric Inhibitory Polypeptide Receptor Sales by Type
6.3 APAC Gastric Inhibitory Polypeptide Receptor Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Gastric Inhibitory Polypeptide Receptor by Country
  7.1.1 Europe Gastric Inhibitory Polypeptide Receptor Sales by Country (2017-2022)
  7.1.2 Europe Gastric Inhibitory Polypeptide Receptor Revenue by Country (2017-2022)
7.2 Europe Gastric Inhibitory Polypeptide Receptor Sales by Type
7.3 Europe Gastric Inhibitory Polypeptide Receptor Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Gastric Inhibitory Polypeptide Receptor by Country
  8.1.1 Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales by Country (2017-2022)
  8.1.2 Middle East & Africa Gastric Inhibitory Polypeptide Receptor Revenue by Country (2017-2022)
8.2 Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales by Type
8.3 Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Gastric Inhibitory Polypeptide Receptor
10.3 Manufacturing Process Analysis of Gastric Inhibitory Polypeptide Receptor
10.4 Industry Chain Structure of Gastric Inhibitory Polypeptide Receptor

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Gastric Inhibitory Polypeptide Receptor Distributors
11.3 Gastric Inhibitory Polypeptide Receptor Customer

12 WORLD FORECAST REVIEW FOR GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR BY GEOGRAPHIC REGION

12.1 Global Gastric Inhibitory Polypeptide Receptor Market Size Forecast by Region
  12.1.1 Global Gastric Inhibitory Polypeptide Receptor Forecast by Region (2023-2028)
  12.1.2 Global Gastric Inhibitory Polypeptide Receptor Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Gastric Inhibitory Polypeptide Receptor Forecast by Type
12.7 Global Gastric Inhibitory Polypeptide Receptor Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Alchemia Limited
  13.1.1 Alchemia Limited Company Information
  13.1.2 Alchemia Limited Gastric Inhibitory Polypeptide Receptor Product Offered
  13.1.3 Alchemia Limited Gastric Inhibitory Polypeptide Receptor Sales, Revenue, Price and Gross Margin (2020-2022)
  13.1.4 Alchemia Limited Main Business Overview
  13.1.5 Alchemia Limited Latest Developments
13.2 AstraZeneca Plc
  13.2.1 AstraZeneca Plc Company Information
  13.2.2 AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Product Offered
  13.2.3 AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Sales, Revenue, Price and Gross Margin (2020-2022)
  13.2.4 AstraZeneca Plc Main Business Overview
  13.2.5 AstraZeneca Plc Latest Developments
13.3 Carmot Therapeutics, Inc.
  13.3.1 Carmot Therapeutics, Inc. Company Information
  13.3.2 Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Product Offered
  13.3.3 Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Sales, Revenue, Price and Gross Margin (2020-2022)
  13.3.4 Carmot Therapeutics, Inc. Main Business Overview
  13.3.5 Carmot Therapeutics, Inc. Latest Developments
13.4 Diabetica Limited
  13.4.1 Diabetica Limited Company Information
  13.4.2 Diabetica Limited Gastric Inhibitory Polypeptide Receptor Product Offered
  13.4.3 Diabetica Limited Gastric Inhibitory Polypeptide Receptor Sales, Revenue, Price and Gross Margin (2020-2022)
  13.4.4 Diabetica Limited Main Business Overview
  13.4.5 Diabetica Limited Latest Developments
13.5 Longevity Biotech, Inc
  13.5.1 Longevity Biotech, Inc Company Information
  13.5.2 Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Product Offered
  13.5.3 Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Sales, Revenue, Price and Gross Margin (2020-2022)
  13.5.4 Longevity Biotech, Inc Main Business Overview
  13.5.5 Longevity Biotech, Inc Latest Developments
13.6 Novo Nordisk A/S
  13.6.1 Novo Nordisk A/S Company Information
  13.6.2 Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Product Offered
  13.6.3 Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Sales, Revenue, Price and Gross Margin (2020-2022)
  13.6.4 Novo Nordisk A/S Main Business Overview
  13.6.5 Novo Nordisk A/S Latest Developments
13.7 Sanofi
  13.7.1 Sanofi Company Information
  13.7.2 Sanofi Gastric Inhibitory Polypeptide Receptor Product Offered
  13.7.3 Sanofi Gastric Inhibitory Polypeptide Receptor Sales, Revenue, Price and Gross Margin (2020-2022)
  13.7.4 Sanofi Main Business Overview
  13.7.5 Sanofi Latest Developments
13.8 Zealand Pharma A/S
  13.8.1 Zealand Pharma A/S Company Information
  13.8.2 Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Product Offered
  13.8.3 Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Sales, Revenue, Price and Gross Margin (2020-2022)
  13.8.4 Zealand Pharma A/S Main Business Overview
  13.8.5 Zealand Pharma A/S Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Gastric Inhibitory Polypeptide Receptor Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Gastric Inhibitory Polypeptide Receptor Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of HM-15211
Table 4. Major Players of LBT-6030
Table 5. Major Players of LY-3298176
Table 6. Major Players of NNC-92041706
Table 7. Major Players of Others
Table 8. Global Gastric Inhibitory Polypeptide Receptor Sales by Type (2017-2022) & (K Pcs)
Table 9. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2017-2022)
Table 10. Global Gastric Inhibitory Polypeptide Receptor Revenue by Type (2017-2022) & ($ million)
Table 11. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Type (2017-2022)
Table 12. Global Gastric Inhibitory Polypeptide Receptor Sale Price by Type (2017-2022) & (USD/Pcs)
Table 13. Global Gastric Inhibitory Polypeptide Receptor Sales by Application (2017-2022) & (K Pcs)
Table 14. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2017-2022)
Table 15. Global Gastric Inhibitory Polypeptide Receptor Revenue by Application (2017-2022)
Table 16. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Application (2017-2022)
Table 17. Global Gastric Inhibitory Polypeptide Receptor Sale Price by Application (2017-2022) & (USD/Pcs)
Table 18. Global Gastric Inhibitory Polypeptide Receptor Sales by Company (2020-2022) & (K Pcs)
Table 19. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Company (2020-2022)
Table 20. Global Gastric Inhibitory Polypeptide Receptor Revenue by Company (2020-2022) ($ Millions)
Table 21. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Company (2020-2022)
Table 22. Global Gastric Inhibitory Polypeptide Receptor Sale Price by Company (2020-2022) & (USD/Pcs)
Table 23. Key Manufacturers Gastric Inhibitory Polypeptide Receptor Producing Area Distribution and Sales Area
Table 24. Players Gastric Inhibitory Polypeptide Receptor Products Offered
Table 25. Gastric Inhibitory Polypeptide Receptor Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Gastric Inhibitory Polypeptide Receptor Sales by Geographic Region (2017-2022) & (K Pcs)
Table 29. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share Geographic Region (2017-2022)
Table 30. Global Gastric Inhibitory Polypeptide Receptor Revenue by Geographic Region (2017-2022) & ($ millions)
Table 31. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Geographic Region (2017-2022)
Table 32. Global Gastric Inhibitory Polypeptide Receptor Sales by Country/Region (2017-2022) & (K Pcs)
Table 33. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Country/Region (2017-2022)
Table 34. Global Gastric Inhibitory Polypeptide Receptor Revenue by Country/Region (2017-2022) & ($ millions)
Table 35. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Country/Region (2017-2022)
Table 36. Americas Gastric Inhibitory Polypeptide Receptor Sales by Country (2017-2022) & (K Pcs)
Table 37. Americas Gastric Inhibitory Polypeptide Receptor Sales Market Share by Country (2017-2022)
Table 38. Americas Gastric Inhibitory Polypeptide Receptor Revenue by Country (2017-2022) & ($ Millions)
Table 39. Americas Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Country (2017-2022)
Table 40. Americas Gastric Inhibitory Polypeptide Receptor Sales by Type (2017-2022) & (K Pcs)
Table 41. Americas Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2017-2022)
Table 42. Americas Gastric Inhibitory Polypeptide Receptor Sales by Application (2017-2022) & (K Pcs)
Table 43. Americas Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2017-2022)
Table 44. APAC Gastric Inhibitory Polypeptide Receptor Sales by Region (2017-2022) & (K Pcs)
Table 45. APAC Gastric Inhibitory Polypeptide Receptor Sales Market Share by Region (2017-2022)
Table 46. APAC Gastric Inhibitory Polypeptide Receptor Revenue by Region (2017-2022) & ($ Millions)
Table 47. APAC Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Region (2017-2022)
Table 48. APAC Gastric Inhibitory Polypeptide Receptor Sales by Type (2017-2022) & (K Pcs)
Table 49. APAC Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2017-2022)
Table 50. APAC Gastric Inhibitory Polypeptide Receptor Sales by Application (2017-2022) & (K Pcs)
Table 51. APAC Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2017-2022)
Table 52. Europe Gastric Inhibitory Polypeptide Receptor Sales by Country (2017-2022) & (K Pcs)
Table 53. Europe Gastric Inhibitory Polypeptide Receptor Sales Market Share by Country (2017-2022)
Table 54. Europe Gastric Inhibitory Polypeptide Receptor Revenue by Country (2017-2022) & ($ Millions)
Table 55. Europe Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Country (2017-2022)
Table 56. Europe Gastric Inhibitory Polypeptide Receptor Sales by Type (2017-2022) & (K Pcs)
Table 57. Europe Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2017-2022)
Table 58. Europe Gastric Inhibitory Polypeptide Receptor Sales by Application (2017-2022) & (K Pcs)
Table 59. Europe Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2017-2022)
Table 60. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales by Country (2017-2022) & (K Pcs)
Table 61. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales Market Share by Country (2017-2022)
Table 62. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Revenue by Country (2017-2022) & ($ Millions)
Table 63. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Country (2017-2022)
Table 64. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales by Type (2017-2022) & (K Pcs)
Table 65. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2017-2022)
Table 66. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales by Application (2017-2022) & (K Pcs)
Table 67. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2017-2022)
Table 68. Key Market Drivers & Growth Opportunities of Gastric Inhibitory Polypeptide Receptor
Table 69. Key Market Challenges & Risks of Gastric Inhibitory Polypeptide Receptor
Table 70. Key Industry Trends of Gastric Inhibitory Polypeptide Receptor
Table 71. Gastric Inhibitory Polypeptide Receptor Raw Material
Table 72. Key Suppliers of Raw Materials
Table 73. Gastric Inhibitory Polypeptide Receptor Distributors List
Table 74. Gastric Inhibitory Polypeptide Receptor Customer List
Table 75. Global Gastric Inhibitory Polypeptide Receptor Sales Forecast by Region (2023-2028) & (K Pcs)
Table 76. Global Gastric Inhibitory Polypeptide Receptor Sales Market Forecast by Region
Table 77. Global Gastric Inhibitory Polypeptide Receptor Revenue Forecast by Region (2023-2028) & ($ millions)
Table 78. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share Forecast by Region (2023-2028)
Table 79. Americas Gastric Inhibitory Polypeptide Receptor Sales Forecast by Country (2023-2028) & (K Pcs)
Table 80. Americas Gastric Inhibitory Polypeptide Receptor Revenue Forecast by Country (2023-2028) & ($ millions)
Table 81. APAC Gastric Inhibitory Polypeptide Receptor Sales Forecast by Region (2023-2028) & (K Pcs)
Table 82. APAC Gastric Inhibitory Polypeptide Receptor Revenue Forecast by Region (2023-2028) & ($ millions)
Table 83. Europe Gastric Inhibitory Polypeptide Receptor Sales Forecast by Country (2023-2028) & (K Pcs)
Table 84. Europe Gastric Inhibitory Polypeptide Receptor Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales Forecast by Country (2023-2028) & (K Pcs)
Table 86. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Revenue Forecast by Country (2023-2028) & ($ millions)
Table 87. Global Gastric Inhibitory Polypeptide Receptor Sales Forecast by Type (2023-2028) & (K Pcs)
Table 88. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share Forecast by Type (2023-2028)
Table 89. Global Gastric Inhibitory Polypeptide Receptor Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 90. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share Forecast by Type (2023-2028)
Table 91. Global Gastric Inhibitory Polypeptide Receptor Sales Forecast by Application (2023-2028) & (K Pcs)
Table 92. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share Forecast by Application (2023-2028)
Table 93. Global Gastric Inhibitory Polypeptide Receptor Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 94. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share Forecast by Application (2023-2028)
Table 95. Alchemia Limited Basic Information, Gastric Inhibitory Polypeptide Receptor Manufacturing Base, Sales Area and Its Competitors
Table 96. Alchemia Limited Gastric Inhibitory Polypeptide Receptor Product Offered
Table 97. Alchemia Limited Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 98. Alchemia Limited Main Business
Table 99. Alchemia Limited Latest Developments
Table 100. AstraZeneca Plc Basic Information, Gastric Inhibitory Polypeptide Receptor Manufacturing Base, Sales Area and Its Competitors
Table 101. AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Product Offered
Table 102. AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 103. AstraZeneca Plc Main Business
Table 104. AstraZeneca Plc Latest Developments
Table 105. Carmot Therapeutics, Inc. Basic Information, Gastric Inhibitory Polypeptide Receptor Manufacturing Base, Sales Area and Its Competitors
Table 106. Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Product Offered
Table 107. Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 108. Carmot Therapeutics, Inc. Main Business
Table 109. Carmot Therapeutics, Inc. Latest Developments
Table 110. Diabetica Limited Basic Information, Gastric Inhibitory Polypeptide Receptor Manufacturing Base, Sales Area and Its Competitors
Table 111. Diabetica Limited Gastric Inhibitory Polypeptide Receptor Product Offered
Table 112. Diabetica Limited Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 113. Diabetica Limited Main Business
Table 114. Diabetica Limited Latest Developments
Table 115. Longevity Biotech, Inc Basic Information, Gastric Inhibitory Polypeptide Receptor Manufacturing Base, Sales Area and Its Competitors
Table 116. Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Product Offered
Table 117. Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 118. Longevity Biotech, Inc Main Business
Table 119. Longevity Biotech, Inc Latest Developments
Table 120. Novo Nordisk A/S Basic Information, Gastric Inhibitory Polypeptide Receptor Manufacturing Base, Sales Area and Its Competitors
Table 121. Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Product Offered
Table 122. Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 123. Novo Nordisk A/S Main Business
Table 124. Novo Nordisk A/S Latest Developments
Table 125. Sanofi Basic Information, Gastric Inhibitory Polypeptide Receptor Manufacturing Base, Sales Area and Its Competitors
Table 126. Sanofi Gastric Inhibitory Polypeptide Receptor Product Offered
Table 127. Sanofi Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 128. Sanofi Main Business
Table 129. Sanofi Latest Developments
Table 130. Zealand Pharma A/S Basic Information, Gastric Inhibitory Polypeptide Receptor Manufacturing Base, Sales Area and Its Competitors
Table 131. Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Product Offered
Table 132. Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 133. Zealand Pharma A/S Main Business
Table 134. Zealand Pharma A/S Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Gastric Inhibitory Polypeptide Receptor
Figure 2. Gastric Inhibitory Polypeptide Receptor Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Gastric Inhibitory Polypeptide Receptor Sales Growth Rate 2017-2028 (K Pcs)
Figure 7. Global Gastric Inhibitory Polypeptide Receptor Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Gastric Inhibitory Polypeptide Receptor Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of HM-15211
Figure 10. Product Picture of LBT-6030
Figure 11. Product Picture of LY-3298176
Figure 12. Product Picture of NNC-92041706
Figure 13. Product Picture of Others
Figure 14. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type in 2021
Figure 15. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Type (2017-2022)
Figure 16. Gastric Inhibitory Polypeptide Receptor Consumed in Metabolic Disorder
Figure 17. Global Gastric Inhibitory Polypeptide Receptor Market: Metabolic Disorder (2017-2022) & (K Pcs)
Figure 18. Gastric Inhibitory Polypeptide Receptor Consumed in Type 2 Diabetes
Figure 19. Global Gastric Inhibitory Polypeptide Receptor Market: Type 2 Diabetes (2017-2022) & (K Pcs)
Figure 20. Gastric Inhibitory Polypeptide Receptor Consumed in Obesity
Figure 21. Global Gastric Inhibitory Polypeptide Receptor Market: Obesity (2017-2022) & (K Pcs)
Figure 22. Gastric Inhibitory Polypeptide Receptor Consumed in Others
Figure 23. Global Gastric Inhibitory Polypeptide Receptor Market: Others (2017-2022) & (K Pcs)
Figure 24. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2017-2022)
Figure 25. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Application in 2021
Figure 26. Gastric Inhibitory Polypeptide Receptor Revenue Market by Company in 2021 ($ Million)
Figure 27. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Company in 2021
Figure 28. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Geographic Region (2017-2022)
Figure 29. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Geographic Region in 2021
Figure 30. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Region (2017-2022)
Figure 31. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Country/Region in 2021
Figure 32. Americas Gastric Inhibitory Polypeptide Receptor Sales 2017-2022 (K Pcs)
Figure 33. Americas Gastric Inhibitory Polypeptide Receptor Revenue 2017-2022 ($ Millions)
Figure 34. APAC Gastric Inhibitory Polypeptide Receptor Sales 2017-2022 (K Pcs)
Figure 35. APAC Gastric Inhibitory Polypeptide Receptor Revenue 2017-2022 ($ Millions)
Figure 36. Europe Gastric Inhibitory Polypeptide Receptor Sales 2017-2022 (K Pcs)
Figure 37. Europe Gastric Inhibitory Polypeptide Receptor Revenue 2017-2022 ($ Millions)
Figure 38. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales 2017-2022 (K Pcs)
Figure 39. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Revenue 2017-2022 ($ Millions)
Figure 40. Americas Gastric Inhibitory Polypeptide Receptor Sales Market Share by Country in 2021
Figure 41. Americas Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Country in 2021
Figure 42. United States Gastric Inhibitory Polypeptide Receptor Revenue Growth 2017-2022 ($ Millions)
Figure 43. Canada Gastric Inhibitory Polypeptide Receptor Revenue Growth 2017-2022 ($ Millions)
Figure 44. Mexico Gastric Inhibitory Polypeptide Receptor Revenue Growth 2017-2022 ($ Millions)
Figure 45. Brazil Gastric Inhibitory Polypeptide Receptor Revenue Growth 2017-2022 ($ Millions)
Figure 46. APAC Gastric Inhibitory Polypeptide Receptor Sales Market Share by Region in 2021
Figure 47. APAC Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Regions in 2021
Figure 48. China Gastric Inhibitory Polypeptide Receptor Revenue Growth 2017-2022 ($ Millions)
Figure 49. Japan Gastric Inhibitory Polypeptide Receptor Revenue Growth 2017-2022 ($ Millions)
Figure 50. South Korea Gastric Inhibitory Polypeptide Receptor Revenue Growth 2017-2022 ($ Millions)
Figure 51. Southeast Asia Gastric Inhibitory Polypeptide Receptor Revenue Growth 2017-2022 ($ Millions)
Figure 52. India Gastric Inhibitory Polypeptide Receptor Revenue Growth 2017-2022 ($ Millions)
Figure 53. Australia Gastric Inhibitory Polypeptide Receptor Revenue Growth 2017-2022 ($ Millions)
Figure 54. Europe Gastric Inhibitory Polypeptide Receptor Sales Market Share by Country in 2021
Figure 55. Europe Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Country in 2021
Figure 56. Germany Gastric Inhibitory Polypeptide Receptor Revenue Growth 2017-2022 ($ Millions)
Figure 57. France Gastric Inhibitory Polypeptide Receptor Revenue Growth 2017-2022 ($ Millions)
Figure 58. UK Gastric Inhibitory Polypeptide Receptor Revenue Growth 2017-2022 ($ Millions)
Figure 59. Italy Gastric Inhibitory Polypeptide Receptor Revenue Growth 2017-2022 ($ Millions)
Figure 60. Russia Gastric Inhibitory Polypeptide Receptor Revenue Growth 2017-2022 ($ Millions)
Figure 61. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales Market Share by Country in 2021
Figure 62. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Country in 2021
Figure 63. Egypt Gastric Inhibitory Polypeptide Receptor Revenue Growth 2017-2022 ($ Millions)
Figure 64. South Africa Gastric Inhibitory Polypeptide Receptor Revenue Growth 2017-2022 ($ Millions)
Figure 65. Israel Gastric Inhibitory Polypeptide Receptor Revenue Growth 2017-2022 ($ Millions)
Figure 66. Turkey Gastric Inhibitory Polypeptide Receptor Revenue Growth 2017-2022 ($ Millions)
Figure 67. GCC Country Gastric Inhibitory Polypeptide Receptor Revenue Growth 2017-2022 ($ Millions)
Figure 68. Manufacturing Cost Structure Analysis of Gastric Inhibitory Polypeptide Receptor in 2021
Figure 69. Manufacturing Process Analysis of Gastric Inhibitory Polypeptide Receptor
Figure 70. Industry Chain Structure of Gastric Inhibitory Polypeptide Receptor
Figure 71. Channels of Distribution
Figure 72. Distributors Profiles